Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss anti–CTLA-4 strategies in the treatment of cancer
- Summarize monoclonal antibodies currently approved or under evaluation for the treatment of cancer
- Describe immunotherapeutic vaccines, including whole tumor cell, peptide, and dendritic cell vaccines
- Describe toxicities associated with immunotherapies
Topics covered include:
- The Role of the Immune System in Cancer
- Overview of Cancer Immunotherapy
- Enhancement of the Antitumor Immune Response: Cytokine-Based Therapy
- Monoclonal Antibodies Targeting Overexpressed Tumor-Specific Antigens: Trastuzumab
- Monoclonal Antibodies Targeting Overexpressed Tumor-Specific Antigens: Cetuximab and Panitumumab
- Monoclonal Antibodies Targeting Overexpressed Tumor-Specific Antigens: Bevacizumab
- Monoclonal Antibodies Targeting Overexpressed Tumor-Specific Antigens: B-Cell Antigens
- Targeting Cytotoxic Agents Directly Toward Tumor Cells: Antibody Conjugates
- Increasing the Immune Response With Immunostimulatory Monoclonal Antibodies: Anti-CTLA4
- Increasing the Immune Response with Immunostimulatory Agonists for Toll-Like Receptors
- Whole Tumor Cell–Based Approaches for the Development of Cancer Vaccines
- Dendritic Cell Activation of the Antitumor Immune Response: Dendritic Cell-Based Vaccines
- Defined Approaches to Cancer Vaccine Therapy: Peptide and DNA Vaccines
- Conclusions